PHARMING GROUP NV (PHARM.AS)
NL0010391025 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 61.52M | 207.34M | 191.92M | 205.16M | 74.35M | |||
| Marketable Securities | 151.68M | N/A | N/A | N/A | N/A | |||
| Receivables | 42.62M | 25.33M | 27.59M | 31.88M | 28.86M | |||
| Inventories | 56.76M | 42.33M | 27.31M | 21.16M | 16.22M | |||
| Other Current Assets | 3.54M | 2.50M | 2.62M | 5.01M | 0.00 | |||
| Total Current Assets | 316.34M | 277.50M | 249.44M | 263.21M | 119.44M | |||
| Non-Current Assets | ||||||||
| PPE Net | 33.47M | 39.15M | 33.16M | 21.65M | 16.30M | |||
| Investments And Advances | 10.40M | 9.73M | 8.65M | 7.12M | 6.18M | |||
| Intangibles | 71.27M | 75.12M | 83.83M | 94.08M | 79.40M | |||
| Other Non-Current Assets | 31.38M | 24.30M | 22.22M | 32.39M | 34.60M | |||
| Total Non-Current Assets | 146.51M | 148.30M | 147.87M | 155.24M | 136.48M | |||
| TOTAL ASSETS | 462.85M | 425.80M | 397.31M | 418.45M | 255.91M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 5.44M | 5.23M | 4.30M | 4.00M | 53.31M | |||
| Accrued Expenses | 56.51M | 45.71M | 34.84M | 616.00K | -210.00K | |||
| Accounts Payable | 16.02M | 8.75M | 7.63M | 47.05M | 40.65M | |||
| Other Current Liabilities | N/A | 0.00 | 0.00 | 25.18M | 20.30M | |||
| Total Current Liabilities | 77.97M | 59.70M | 46.77M | 76.85M | 114.25M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 166.10M | 161.46M | 157.46M | 157.96M | 4.89M | |||
| Deferred Taxes/Income | N/A | N/A | N/A | N/A | 2.34M | |||
| Other Non-Current Liabilities | N/A | 0.00 | 165.00K | 212.00K | 19.38M | |||
| Total Non-Current Liabilities | 166.10M | 161.46M | 157.63M | 158.17M | 24.27M | |||
| TOTAL LIABILITIES | 244.07M | 221.16M | 204.40M | 235.02M | 138.53M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -267.32M | -265.17M | -269.77M | -271.01M | -331.79M | |||
| Additional Paid In Capital | 478.43M | 462.30M | 455.25M | 447.13M | 441.95M | |||
| Minority Interest | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 7.67M | 7.51M | 7.43M | 7.31M | 7.23M | |||
| Shares Outstanding | 671.07M | 656.35M | 648.75M | 638.82M | 631.32M | |||
| Tangible Book Value per Share | 0.22 | 0.20 | 0.17 | 0.14 | 0.06 | |||
| Total Shareholders' Equity | 218.78M | 204.64M | 192.92M | 183.44M | 117.39M | |||
| TOTAL LIABILITIES AND EQUITY | 462.85M | 425.80M | 397.31M | 418.45M | 255.91M | |||
| Statistics | ||||||||
| Debt/Equity | 0.76 | 0.79 | 0.82 | 0.86 | 0.04 | |||
| Current Ratio | 4.06 | 4.65 | 5.33 | 3.43 | 1.05 | |||
| Return On Assets (ROA) | -2.28% | 3.21% | 4.03% | 9.02% | 15.00% | |||
| Return On Equity (ROE) | -4.82% | 6.68% | 8.29% | 20.58% | 32.70% | |||
| Return On Invested Capital (ROIC) | N/A | 2.12% | 5.13% | 16.74% | 34.20% | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | 4.90% | 11.35% | 41.92% | 71.97% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | 9.30% | 24.07% | 135.01% | N/A | |||
All data in USD